Overview of Dr. Mehrazin
Dr. Mehrazin’s clinical expertise is in robotic surgery, laparoscopic, and open surgical techniques for the treatment of various urologic cancers, which allows him to tailor a specific treatment plan based on individual patient need and preferences. He is one of the few urologists in the region who has extensive training and certified in performing minimally invasive organ preserving and reconstructive techniques to preserve function and quality of life for patients with kidney cancer and bladder cancer. He performs both robotic (using da Vinci® technology) and open cystectomies with continent urinary diversion (new bladder), nephron-sparing (kidney preserving) partial nephrectomy, nerve-sparing prostatectomy, partial or total adrenalectomy, retroperitoneal lymph node dissection for testicular cancer, and endoscopic nephron-sparing management of patients with upper tract urothelial carcinomas. He also has a special clinical interest in the management of patients with metastatic and advanced kidney cancer with tumors extending into the surrounding organs or major vessels, as well as salvage bladder surgeries following radiation therapy.
Office
1 Gustave L Levy Pl
# 1272
New York, NY 10029Fax+1 212-987-4675
Education & Training
- Temple University HospitalFellowship, Minimally Invasive Urologic Surgery, 2012 - 2014
- University of TennesseeResidency, Urology, 2008 - 2012
- University of TennesseeInternship, Transitional Year, 2007 - 2008
- Medical University of the AmericasClass of 2006
Certifications & Licensure
- NY State Medical License 2014 - 2025
- PA State Medical License 2011 - 2014
- American Board of Urology Urology
- Society of Urologic OncologySociety of Urologic Oncology
Clinical Trials
- Use of Perioperative Pain Blocks In Urological Surgery Start of enrollment: 2019 Nov 11
Publications & Presentations
PubMed
- 3 citationsRobotic-Assisted Partial Nephrectomy and Adrenalectomy: Case of a Pheochromocytoma Invading into Renal Parenchyma.Zeynep Gul, Christine W. Liaw, Avinash Reddy, Reza Mehrazin
Case Reports in Urology. 2020-06-20 - 29 citationsGemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.Matthew D Galsky, Siamak Daneshmand, Sudeh Izadmehr, Edgar Gonzalez-Kozlova, Kevin G Chan
Nature Medicine. 2023-11-01 - 40 citationsNKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer.Bérengère Salomé, John P Sfakianos, Daniel Ranti, Jorge Daza, Christine Bieber
Cancer Cell. 2022-09-12
Journal Articles
- Lymphopenia as an independent predictor of worse survival in papillary renal cell carcinoma.Reza Mehrazin, Robert G. Uzzo, Alexander Kutikov, Jeffrey J. Tomaszewski, Serge Ginzburg, Karen J. Ruth, Essel Al-Saleem, David Y. T. Chen, Rosalia Viterbo, Richard E...., J Clin Oncol 32, 2014 (suppl 4; abstr 397)
Press Mentions
- Novel Chemotherapy Delivery System May Fill Key Gap in Bladder Cancer TreatmentMay 3rd, 2023
- Minimally Invasive Partial Nephrectomy Does Not Worsen Cancer OutcomesFebruary 25th, 2022
- Kidney Cancer Gets Too Little AttentionOctober 11th, 2015
- Join now to see all
Professional Memberships
- Member
- Member
- Society of Urologic OncologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: